Ipsen

Ipsen EBIT Margin

The EBIT Margin (Operating Margin) of Ipsen (IPN.PA) as of Sep 21, 2026 is 20.30 %. In the previous year, EBIT Margin (Operating Margin) was 13.90 % — a change of 46.11% (higher).

EBIT Margin

20.30 %

YoY

46.11%

Last updated:

EBIT Margin (Operating Margin) of Ipsen is 2026 20.30 % . EBIT Margin (Operating Margin) of Ipsen was 2025 13.90 % . It decreases by 46.11% higher compared to the previous year.

For Ipsen, the operating (EBIT) margin of 20.3% is down versus 32.2% a few years ago.

The Ipsen EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
23.65 EUR
Jan 1, 2019
26.06 EUR
Jan 1, 2020
28.26 EUR
Jan 1, 2021
32.24 EUR
Jan 1, 2022
29.90 EUR
Jan 1, 2023
24.68 EUR
Jan 1, 2024
13.90 EUR
Jan 1, 2025
20.30 EUR
The Ipsen EBIT Margin history
YEAREBIT MarginYoY
20.30 %+46.11%
13.90 %-43.70%
24.68 %-17.45%
29.90 %-7.27%
32.24 %+14.11%
28.26 %+8.42%
26.06 %+10.22%
23.65 %+18.81%
19.90 %-4.48%
20.84 %+1.01%
20.63 %+10.16%
18.73 %+10,511.18%
0.18 %+96.36%
0.09 %+46.45%
0.06 %-44.24%
0.11 %-29.01%
0.16 %-10.62%
0.17 %-17.47%
0.21 %-3.26%
0.22 %
Access this data via the Eulerpool API

Ipsen Stock analysis

What does Ipsen do? Ipsen SA is a French biopharmaceutical company specialized in the development of drugs for the treatment of cancer, neurological disorders, and endocrine disorders. It was founded in 1929 by a pharmacist named Henri Beaufour and is headquartered in Paris. The history of Ipsen began with the production of extraction products from snake venom for the manufacturing of serum against tetanus and diphtheria. In the 1960s, the company started to focus on the production of hormones and peptides, with a focus on endocrine disorders. In the 1990s, Ipsen expanded its product portfolio to include oncology and neurological disorders. Ipsen's business model focuses on research and development of new drugs, as well as marketing of already established drugs in selected markets worldwide. The company employs around 5,700 employees and operates in more than 115 countries. Ipsen has two main business segments: specialty drugs and consumer healthcare. The specialty drugs segment focuses on the development and marketing of innovative therapies in the areas of oncology, endocrinology, and neuroscience. Ipsen's most well-known products include Somatuline, a drug for the treatment of acromegaly, and Decapeptyl, a drug for the treatment of prostate cancer and endometriosis. In the consumer healthcare segment, Ipsen is mainly specialized in the production of drugs for the treatment of gastrointestinal disorders and cold and flu symptoms. Some well-known brands include Smecta, a drug for diarrhea, and Nurofen, a pain reliever. Ipsen also has a strong presence in the field of aesthetic medicine, where the company operates a subsidiary called Ipsen Aesthetic. This subsidiary develops and markets products for the treatment of wrinkles and other signs of aging on the skin. Well-known brands of Ipsen Aesthetic include Dysport, a botulinum toxin product for the treatment of wrinkles, and the filler Restylane. Overall, Ipsen has established itself as a leading biopharmaceutical company focused on the development and marketing of products in specialized therapy areas. The company has a strong pipeline of new products in development and remains an important player in the pharmaceutical industry due to its strong scientific expertise and global presence. Ipsen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ipsen stock

EBIT Margin (Operating Margin) of Ipsen is 20.30 % in 2026.

EBIT Margin (Operating Margin) of Ipsen changed from 13.90 % to 20.30 %, representing a 46.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Ipsen since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Ipsen with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

Margins — Ipsen

All Key Metrics — Ipsen